- Home
- ADIL vs GRI Comparison
ADIL vs GRI Comparison
Compare ADIL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- GRI
- Stock Information
- Founded
- ADIL 2010
- GRI 2018
- Country
- ADIL United States
- GRI United States
- Employees
- ADIL N/A
- GRI N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- GRI Health Care
- Exchange
- ADIL Nasdaq
- GRI Nasdaq
- Market Cap
- ADIL 4.8M
- GRI 5.6M
- IPO Year
- ADIL 2018
- GRI N/A
- Fundamental
- Price
- ADIL $0.79
- GRI $0.42
- Analyst Decision
- ADIL Strong Buy
- GRI Strong Buy
- Analyst Count
- ADIL 1
- GRI 2
- Target Price
- ADIL $8.00
- GRI $11.50
- AVG Volume (30 Days)
- ADIL 172.8K
- GRI 181.8K
- Earning Date
- ADIL 03-31-2025
- GRI 03-27-2025
- Dividend Yield
- ADIL N/A
- GRI N/A
- EPS Growth
- ADIL N/A
- GRI N/A
- EPS
- ADIL N/A
- GRI N/A
- Revenue
- ADIL N/A
- GRI N/A
- Revenue This Year
- ADIL N/A
- GRI N/A
- Revenue Next Year
- ADIL N/A
- GRI N/A
- P/E Ratio
- ADIL N/A
- GRI N/A
- Revenue Growth
- ADIL N/A
- GRI N/A
- 52 Week Low
- ADIL $0.72
- GRI $0.30
- 52 Week High
- ADIL $4.17
- GRI $12.31
- Technical
- Relative Strength Index (RSI)
- ADIL 40.52
- GRI 28.18
- Support Level
- ADIL $0.76
- GRI $0.43
- Resistance Level
- ADIL $0.85
- GRI $0.60
- Average True Range (ATR)
- ADIL 0.05
- GRI 0.06
- MACD
- ADIL 0.01
- GRI -0.00
- Stochastic Oscillator
- ADIL 50.77
- GRI 10.91
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.